Commission and EIB provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing

vaccinations CDC

(CDC, Unsplash)

This article is brought to you in association with the European Commission.


  • European Investment Bank and CureVac sign €75 million loan agreement for the development and large-scale production of vaccines, including CureVac’s vaccine candidate against SARS-CoV-2
  • The EIB loan will support CureVac’s activities to complete its new messenger ribonucleic acid (mRNA) production facility in Tübingen, Germany
  • The transaction is financed under the Infectious Diseases Finance Facility of Horizon 2020, the EU research and innovation programme for 2014-2020

The European Investment Bank (EIB) and CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimised mRNA, entered into a €75 million loan agreement to support the Company’s ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections. In addition, the loan will support the Company’s efforts to expand its existing Good Manufacturing Practice (GMP) certified production capabilities and accelerate the completion of its fourth production site in Tübingen, Germany. The EIB financing will be provided in three €25 million tranches upon completion of pre-defined milestones.

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: “The coronavirus will be with us, as long as we do not have a vaccine against it. This is why our work on this front, together with international actors, is so crucial. Recently we have presented our vaccines strategy to accelerate the development, manufacturing and deployment of vaccines against the novel coronavirus. And since the beginning of the pandemic, we increased the funding for the Infectious Diseases Finance Facility by €400 million to allow the EIB to process a higher volume of projects addressing this disease. With our support to CureVac we accelerate our efforts to find safe and effective solutions for everyone in Europe and globally.”

It does not need a pandemic to prove that new vaccines can be breakthroughs for public health,” said Ambroise Fayolle, EIB Vice-President in charge of innovation and health. “But in times like ours it becomes clear just how important they are to keep societies running globally. In fact, the only way to end the dramatic situation the world is facing since the outbreak of the COVID-19 pandemic would be a safe and effective vaccine. Thanks to our cooperation with the European Commission, we can finance more and more innovative biotech and medtech companies, such as CureVac, in their research and development of vaccines, therapeutics and diagnostics solutions. This is an added value of Europe, and the EIB does everything it can to maximise this value for the sake of people.”

Pierre Kemula, Chief Financial Officer of CureVac, added: “We are very pleased with the EIB financing. It allows us to further invest in our mRNA technology platform to fight life-threatening diseases. We are working intensively to develop a safe and effective low dose mRNA vaccine against SARS-CoV-2 and started a Phase 1 clinical trial of CVnCoV in June. We are looking forward to expediting the completion of our industrial-scale production site to provide critically needed supply of innovative mRNA-based vaccines.”

About CureVac’s mRNA technology platform

CureVac’s mRNA technology platform has shown potential in the clinical development and production of mRNA based vaccines and therapeutics. The Company’s proprietary RNAoptimizer® platform aims to optimize the properties of mRNA medicines based on its three core pillars: protein design, mRNA optimization and mRNA delivery. The technology can be tailored to induce varying degrees of immune responses against specific protein antigens of choice, potentially providing potent prophylactic vaccines for the prevention of infectious diseases at a low dose, such as Rabies, as well as immunotherapies for the treatment of cancer. The technology can also be adapted to avoid immune activation for purposes of protein therapy and antibodies, thereby providing potential new therapeutic modalities for patients suffering from a vast range of diseases.

The Infectious Diseases Finance Facility (IDFF) of the EU’s Horizon 2020 programme backs the loan to CureVac. The IDFF is an example of successful collaboration between the European Commission and the EIB in the face of a health crisis. Through the IDFF, the EIB has supported 13 companies with total lending of €316 million for developing cures, vaccines and diagnostics against various infectious diseases, most prominently the coronavirus.

 

Background

The European Investment Bank is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investments in order to contribute towards EU policy goals. The EIB also supports investments outside the EU.

The InnovFin Infectious Diseases Finance Facility (IDFF) is a financial product dedicated to support the fight against infectious diseases. The joint European Commission and EIB Group initiative falls under Horizon2020, the 2014-2020 EU research and innovation programme. IDFF enables the EIB to provide between €7.5 million and €75 million of funding to innovative players active in developing vaccines, drugs, medical and diagnostic devices and research infrastructure for combatting infectious diseases. The loans finance clinical trials, market access, and the development of prototypes or industrial roll out of novel equipment, pre-clinical R&D and working capital needs. The IDFF has been reinforced by €400 million to better tackle the outbreak of COVID-19.

CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

the sting Milestone

Featured Stings

How to build a more resilient and inclusive global system

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

Stopping antimicrobial resistance would cost just USD 2 per person a year

China is a renewable energy champion. But it’s time for a new approach

250+ senior claims leaders under one roof, exchanging transformation strategy

More needs to be done to bridge the digital gender divide

Parliament commemorates the liberation of Auschwitz 75 years ago

Upgraded EU visa information database to increase security at external borders

Khashoggi murder trials must public and meet international standards, UN expert urges

How LA plans to be 1.6°C cooler by 2050

Seize the opportunities of digital technology to improve well-being but also address the risks

Women’s work faces the greatest risk of automation, says new research

Is a deal over EU budget possible today?

‘Global sisterhood’ tells perpetrators ‘time is up’ for pandemic of violence

WEF Davos 2016 LIVE: “CO2 is not the problem, it is the symptom”, the pilots who crossed the world using solar energy cry out from Davos

“The Belt and Road Initiative should be mutually beneficial for EU and China and every participating country”, Vice-President Papadimoulis of the European Parliament underscores from European Business Summit 2018

Single Market Scoreboard 2020: Member States need to do more to ensure the good functioning of the EU Single Market*

This is what the UK’s major supermarkets say about plastic packaging and the environment

MEPs demand an end to migrant deaths across the Mediterranean Sea

Pakistan’s digital revolution is happening faster than you think

Syria still suffering ‘staggering levels’ of humanitarian need, Security Council hears

From low-earth orbit, ‘envoys’ of humanity join UN space forum

Find unity ‘to halt Libya’s senseless unraveling’, UN envoy urges Security Council

Burnout is a pandemic. Why don’t we talk more about it?

UN chief extends condolences to families of China landslide casualties

Quashing myths on 2019-nCoV for better public management

DR Congo Ebola centre attacks could force retreat against the deadly disease, warns UN health chief

EU-Ukraine Free Trade Agreement sees the light as Moscow’s reaction once more looms

How speaking ‘parentese’ to your child could make them a faster learner

Five-year low inflation for Eurozone and now Mario has to finally wake up the Germans

Idai disaster: Stranded victims still need rescue from heavy rains as UN scales up response

EU-China: Council authorises signature of the agreement on geographical indications

War in Syria: ‘Carnage’, flouting of rights and international law, must stop: Guterres

Youth Forum welcomes European Commission proposal to speed up financing for youth employment

MasterCard at European Business Summit 2015: A focus on innovation will drive inclusive economic growth for Europe

Is technology key to improving global health and education, or just an expensive distraction?

Rule of Law: European Commission refers Poland to the Court of Justice to protect judges from political control

What is behind the wide reach of  fake news about Coronavirus?

EU-Vietnam trade agreement enters into force

Why impoverishment and social exclusion grow in the EU; the affluent north also suffers

COVID-19 and nature are linked. So should be the recovery.

Corporate tax remains a key revenue source, despite falling rates worldwide

Residents and visitors to this Dutch neighborhood could share a pool of cars and bikes

Europe might not avoid new partitioning on Ukrainian crisis

Draghi to hold on zero interest rates until he leaves ECB

This is how drones and other ‘tradetech’ are transforming international trade

Empathy and human connection: how businesses can respond to COVID-19

UNICEF reports uneven progress in 30 years of child rights treaty

3 important lessons from 20 years of working with social entrepreneurs

United States: UN chief ‘deeply saddened’ by deadly California wildfires

Coronavirus: Commission Statement on consulting Member States on proposal to further expand State aid Temporary Framework to recapitalisation measures

Europe united in not supporting a US attack on Syria

These are the world’s 10 most competitive economies in 2019

Apple’s tax avoidance scheme remains as creative as their new iPhone

Practicing healthcare: Skills of a good healthcare professional and its effects

The European Sting live from the World Economic Forum 2015 in Davos

How global tech companies can champion ethical AI

Parliament wants to suspend EU accession negotiations with Turkey

‘Fire-fighting approach’ to humanitarian aid ‘not sustainable’: Deputy UN chief

This is the critical number that shows when housing breaks down

Horn of Africa: UN chief welcomes Djibouti agreement between Eritrea, Ethiopia and Somalia

Guterres appeals for ‘maximum restraint’ over Jammu and Kashmir, as tensions rise

More Stings?

Advertising

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s